A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 649-658

  Trudeau, Caroline ^a   Cotreau, Monette M ^a   Stonis, Lucille ^a   Dykstra, Kevin H ^a,b   Oestreicher, Judy L ^a   Strahs, Andrew ^a   Dorner, Andrew J ^a   Van Cleave, Victor H ^a   Trepicchio, William L ^a,c   Schwertschlag, Ullrich S ^a  

^a PFIZER INC   (United States)

^b PHARSIGHT CORPORATION   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Clinical trial; Healthy volunteers; Interferon (IFN ); Interleukin 12 (IL 12); Signal transducer and activator of transcription (STAT 1)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; PLACEBO; RECOMBINANT INTERLEUKIN 12; STAT PROTEIN;

ADULT; ARTHRALGIA; ARTHROPATHY; ARTICLE; BACKACHE; CHILL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN CELL; INJECTION SITE REACTION; LEG CRAMP; LYMPHADENOPATHY; MALE; MUSCLE RIGIDITY; MYALGIA; NAUSEA; NECK PAIN; NORMAL HUMAN; PAIN; PHARMACOGENOMICS; PHARYNGITIS; PROTEIN EXPRESSION; PRURITUS; SIDE EFFECT; SOMNOLENCE; SWEATING;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-6; MALE; PHARMACOGENETICS; RNA, MESSENGER; TIME FACTORS;

EID: 21044435767     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005276116     Document Type: Article

References (35)

1. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153:1697-1706.
2. Zou JP, Yamamoto N, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995;7:1135-1145.
3. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991;146:3074-3081.
4. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
5. Brunda MJ. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
6. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells. 1994;12:154-168.
7. Nagayama H, Sato K, Kawasaki H, et al. IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte-derived dendritic cells. J Immunol. 2000;165:59-66.
8. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science. 1993;260:496-497.
9. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol. 2000;18:451-494.
10. deJong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280:1435-1438.
11. Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacilli Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest. 1998;102:2035-2040.
12. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 1997;71:3236-3243.
13. Bi Z, Quandt P, Komatsu T, Barna M, Reiss CS. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J Immunol. 1995;155:5684-5689.
14. Matsuo R, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection. J Leukoc Biol. 1996;59:623-630.
15. Sedegah M, Finkelman F, Hoffman SL. Interleukin 12 induction of interferon γ-dependent protection against malaria. Proc Natl Acad Sci U S A. 1994;91:10700-10702.
16. Hoffman SL, Crutcher JM, Puri SK, et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med. 1997;3:80-83.
17. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
18. Schwarze J, Hammelmann E, Cieslewicz G. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol. 1988;102:86-93.
19. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527-1537.
20. Van Ruissen F, Carroll JM, van der Valk PG, Schalkwijk J. Differential effects of detergents on keratinocyte gene expression. J Invest Dermatol. 1998;110:358-363.
21. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675-1680.
22. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 2001;1:272-287.
23. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK. Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome Biol. 2001;2:0055.1-0055.13.
24. Portielje JEA, Kruit WHJ, Schuler M, et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res. 1999;5:3983-3989.
25. Ohno R, Yamaguchi Y, Toge T, et al. A dose-escalation and pharmacokinetic study of subcutaneoulsy administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin Cancer Res. 2000;6:2661-2669.
26. Portielje JEA, Lamers CHJ, Kruit WHJ, et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-γ, IL-6, and IL-8 responses. Clin Cancer Res. 2003;9:76-83.
27. Rakhit A, Yeon MM, Ferrante J, et al. Down-regulation of the pharmacokinetic-pharmacodynamic response to interlekin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this adaptive response in mice. Clin Pharmacol Ther. 1999;65:615-629.
28. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409-417.
29. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood. 1997;90:2541-2548.
30. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res. 1999;5:9-16.
31. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol. 1994;6:157-167.
32. Lenzi R, Rosenblum M, Verschraegen C, et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res. 2002;8:3686-3695.
33. Kovarik J, Boudny V, Kocak I, Lauerova L, Fait V, Vagundova M. Malignant melanoma associates with deficient IFN-induced phosphorylation. Int J Mol Med. 2003;12:335-340.
34. Darnell JE. STATs and gene regulation. Science. 1997;277:1630-1635.
35. Yu CR, Lin JX, Fink DW, Akira S, Bloom ET, Yamauchi A. Differential utilization of janus kinase-signal transducer and activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-γ. J Immunol. 1996;157:126-137.